A number of other equities research analysts also recently commented on the company. Piper Sandler increased their price objective on Rigel Pharmaceuticals from $1.00 to $2.00 and gave the company a “neutral” rating in a research report on Tuesday, August 16th. HC Wainwright increased their price objective on Rigel Pharmaceuticals from $7.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, August 18th. Cantor Fitzgerald lowered Rigel Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $6.00 to $1.00 in a report on Wednesday, June 8th. BMO Capital Markets reduced their target price on Rigel Pharmaceuticals from $7.00 to $3.00 in a report on Thursday, June 9th. Finally, Jefferies Financial Group lowered Rigel Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 8th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $3.96.
Rigel Pharmaceuticals Price Performance
Shares of NASDAQ:RIGL traded down $0.05 on Thursday, reaching $1.16. 3,677,462 shares of the company traded hands, compared to its average volume of 3,877,067. Rigel Pharmaceuticals has a fifty-two week low of $0.64 and a fifty-two week high of $3.91. The company’s 50 day moving average is $1.39 and its 200-day moving average is $1.89. The stock has a market capitalization of $200.49 million, a PE ratio of -2.37 and a beta of 1.54. The company has a debt-to-equity ratio of 4.39, a current ratio of 2.19 and a quick ratio of 2.08.
Hedge Funds Weigh In On Rigel Pharmaceuticals
Rigel Pharmaceuticals Company Profile
Rigel Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia.
- Get a free copy of the StockNews.com research report on Rigel Pharmaceuticals (RIGL)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Rigel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.